Tenant and associated members 
Our database

Heidelberg Technology Park accommodates a variety of companies at five locations in the Heidelberg metropolitan area. In addition, there are associated members who are part of our network - but are based outside the Technology Park. You can use our database to find specific companies or get an overview of the products and services offered within Heidelberg Technology Park.


Apogenix AG

Im Neuenheimer Feld 584
69120 Heidelberg

Phone: +49 6221 586080
Email: contact(at)apogenix.com
Url: www.apogenix.com

Apogenix develops innovative immunoncological protein drugs for the treatment of cancer and other malignant diseases. The company has a promising pipeline of drug candidates that exert their therapeutic effect by influencing various TNFSF (tumor necrosis factor superfamily)-dependent signaling pathways and thus restoring the immune response against tumors. APG101 is being developed for the treatment of solid tumors and malignant hematologic diseases and is in clinical trials for the treatment of glioblastoma, the most common and aggressive brain tumor, and myelodysplastic syndrome (MDS), a stem cell disease that can lead to severe anemia. APG101 has demonstrated statistically significant efficacy in a controlled phase II efficacy study for the second-line treatment of glioblastoma. In particular, APG101 benefited patients in whose tumors a specific biomarker was detectable. Apogenix is developing a companion diagnostic test based on this biomarker to allow patients to benefit from a personalized therapy approach. The CD95 system, which is inhibited by APG101, plays an important role in the progress of many other solid tumors, demonstrating the potential of APG101 for the treatment of various types of cancer. Apogenix's highly qualified scientific team has developed a technology platform to develop novel TNFSF fusion proteins for broad oncology use that offer significant advantages over other biotherapeutics, such as antibodies. TNFSF proteins play a crucial role in regulating the immune response. The company has already successfully licensed the first program based on this technology platform, including the TRAIL receptor agonist APG880, to a large pharmaceutical company. Apogenix is currently working on the development of novel CD40, CD27, OX40, HVEM, GITR and 4-1BB agonists for cancer immunotherapy.

Location: Im Neuenheimer Feld
Status: Tenant

back

Always up-to-date 
Your details

Your company is a tenant in the Heidelberg Technology Park or an associated member, but you cannot find it in our database? Your data is no longer up to date or you would like to complete your profile?

Help us to keep this database as up-to-date and relevant as possible and contact Ms. Julia Niederbühl with your change requests.

This Website uses Cookies

We store technically necessary cookies, without which the operation of the site is not possible. In order to provide you with a better user experience on our website, we would also like to evaluate anonymous analysis data. Which tools we use for this purpose and further information can be found in our Privacy Policy and in our Legal Notice.

Accept technically required cookies only

On our website you will find interesting videos and maps hosted on Youtube/googleMaps. The videos and maps are used without a cookie, but data is still loaded from google servers, which means that your surfing behaviour can be recorded by Google.

Name Google Analytics
Anbieter Google LLC
Zweck Cookie von Goolge für Website-Analysen, mit dem statistische und anonymisierte Daten darüber erfasst werden, wie der Besucher die Website nutzt.
Datenschutzerklärung policies.google.com/privacy
Cookie Name _ga,_gat,_gid
Cookie Laufzeit 14 Monate